Expression of metadherin and vascular endothelial growth factor in epithelial ovarian cancer and its relationship with clinical features of epithelial ovarian cancer
ZHENG Wen-ling HUANG Xiao-ling
Department of Obstetrics and Gynecology, People′s Hospital of Luohu District, Guangdong Province, Shenzhen 518000, China
Abstract:Objective To investigate the expression of metadherin (MTDH) and vascular endothelial growth factor(VEGF) in epithelial ovarian cancer and its association with the clinicopathological features of epithelial ovarian cancer.Methods Forty patients with epithelial ovarian cancer who were admitted to our hospital from February 2017 to January 2019 were enrolled as study group, 20 patients with benign epithelial ovarian cancer were enrolled in the routine group,and 20 healthy people were selected as healthy comparison group.The expressions of MTDH, VEGF mRNA and protein in ovarian epithelial tissues of each group were examined by reverse transcription-polymerase chain reaction (RT-PCR)and immunohistochemical SP method.Results The expressions of MTDH mRNA, VEGF mRNA and the positive expression rates of MTDH and VEGF in patients with different International Federation of Gynecology and Obstetrics (FIGO) stage epithelial ovarian cancer were significantly different (P<0.05).MTDH mRNA and VEGF mRNA in patients with epithelial ovarian cancer with different lymph node spread, there were no significant differences in mRNA expression and positive expression rates of MTDH and VEGF (P>0.05), and there was a positive correlation between the expression of MTDH and VEGF in epithelial ovarian cancer(P<0.05).Conclusion There is a close relationship between VEGF and MTDH and the occurrence and deterioration of epithelial ovarian cancer.
郑文玲; 黄晓玲. 异黏蛋白及血管内皮生长因子在上皮性卵巢癌中的表达及与上皮性卵巢癌临床特征的关系[J]. 中国当代医药, 2020, 27(8): 73-75转79.
ZHENG Wen-ling; HUANG Xiao-ling. Expression of metadherin and vascular endothelial growth factor in epithelial ovarian cancer and its relationship with clinical features of epithelial ovarian cancer. 中国当代医药, 2020, 27(8): 73-75转79.
Janakiram M,Shah UA ,Liu W,et al.The third group of theB7-CD28 immune checkpoint family:HHLA2,TMIGD2,B7x,and B7-H3[J].ImmunolRev,2017,276(1):26-39.
[2]
Kim HS,Kim JY,Lee YJ,et al.Expression of programmedcell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advancedhigh-grade serous ovarian cancer[J].Gynecol Oncol,2018,151(3):414-421.
[3]
Cheng H,Borczuk A,Janakiram M,et al.Wide expressionand significance of alternative immune checkpoint molecules,B7x and HHLA2,in PD-L1-negative human lungcancers[J].Clin Cancer Res,2018,24(8):1954-1964.